- Home
- FTI vs RPRX Comparison
FTI vs RPRX Comparison
Compare FTI & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTI | RPRX |
|---|---|---|
| Founded | 1884 | 1996 |
| Country | United Kingdom | United States |
| Employees | N/A | 100 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6B | 19.5B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FTI | RPRX |
|---|---|---|
| Price | $70.98 | $46.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $61.42 | $47.75 |
| AVG Volume (30 Days) | ★ 3.8M | 2.8M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | 0.29% | ★ 2.06% |
| EPS Growth | ★ 20.42 | N/A |
| EPS | ★ 2.30 | 1.78 |
| Revenue | ★ $9,932,600,000.00 | $2,378,193,000.00 |
| Revenue This Year | $8.53 | $38.30 |
| Revenue Next Year | $5.59 | $4.80 |
| P/E Ratio | $30.47 | ★ $25.62 |
| Revenue Growth | ★ 9.35 | 5.06 |
| 52 Week Low | $22.12 | $29.66 |
| 52 Week High | $70.11 | $47.86 |
Technical Indicators
Market Signals| Indicator | FTI | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 72.29 | 63.77 |
| Support Level | $59.63 | $35.32 |
| Resistance Level | N/A | $47.86 |
| Average True Range (ATR) | 2.24 | 0.77 |
| MACD | 0.31 | -0.14 |
| Stochastic Oscillator | 94.84 | 100.00 |
Price Performance
Historical ComparisonAbout FTI TechnipFMC plc
TechnipFMC is the largest provider of offshore oilfield services, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea construction services. The company also provides various pieces of surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of Technip and FMC Technologies.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.